KOSPIBiotech & Pharma003120

Ilsung IS

₩20,300▼ 1.69%2026-11-18 close
Market Cap
₩216B
Turnover
₩34,307,725
Volume
1.7K
Shares out.
10.6M
PER
19.9×
PBR
0.4×
EPS
₩1,028
Dividend Yield
5.87%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,200 per share · Prices as of the 2026-11-18 close

01

Report overview

Narrowing Losses and Expanded Shareholder Returns; Earnings Recovery Is the Test

Ilsung IS has posted three straight quarters of rising revenue and smaller operating losses through the third quarter of 2026, but five consecutive quarters of operating losses mean sustained profitability remains the open question.

  1. 1

    Third-quarter 2026 revenue reached KRW 19.5 billion, rising for three straight quarters, while the operating loss narrowed to KRW 662 million.

  2. 2

    Operating cash flow turned positive at KRW 3.88 billion in 2025 from a deficit the prior year, yet the company still recorded an operating loss of KRW 6.16 billion and has posted losses for three straight years.

  3. 3

    Cancellation of 2.66 million treasury shares was completed on October 13, 2026, reducing the share count from 13.3 million to 10.64 million.

  4. 4

    Revenue is concentrated in the antibiotic Augmentin, which leaves the company's sales highly dependent on a single product line.

  5. 5

    Net income attributable to controlling shareholders fell 91.1% to KRW 1.17 billion in 2025, and the fourth quarter of 2025 accounts for a large share of the KRW 7.2 billion total over the last four quarters.

02

Business structure

Ilsung IS's core business is supplying prescription drugs (ETC) across several disease areas, including antibiotics, cardiovascular, gastrointestinal and endocrine treatments, to hospitals and clinics.

Its flagship product is the penicillin-class antibiotic Augmentin, which it produces under a long-standing partnership with GSK. A securities research note on the company also describes domestic Augmentin sales as the center of its results. The company describes its production facilities as meeting cGMP standards.

In the first nine months of 2025, declines in tablet and injectable sales drove the overall revenue decline on a standalone basis. Beyond core pharmaceuticals, the company is pursuing contract manufacturing (CMO) expansion, senior healthcare and digital therapeutics (DTx).

Its asset management and real estate development units are also part of the business, and a 2024 report said the real estate development unit leads its nursing facility project.

In its March 2026 corporate value enhancement plan, the company set out a portfolio reshaping focused on profitability, in-house production for key products, and raw material cost reduction.

Developing in-house combination drugs and expanding contract manufacturing were also presented as ways to broaden its earnings base. Segment revenue breakdowns are not presented here; the business remains weighted toward prescription drug sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩16.8B-₩800M−5.0%
2025Q4₩14.7B-₩2B−13.7%
2026Q1₩16.7B-₩500M−3.0%
2026Q2₩17.1B-₩1.6B−9.1%
2026Q3₩19.5B-₩700M−3.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩61.2B₩1.3B₩105.2B2.1%23.6%11.0%
2023₩78.1B-₩8B-₩20.9B−10.2%−5.5%9.5%
2024₩69B-₩9.5B₩13.1B−13.8%3.4%3.0%
2025₩64.3B-₩6.2B₩1.2B−9.6%0.3%4.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On an annual basis, revenue rose 27.4% from KRW 61.2 billion in 2022 to KRW 78.1 billion in 2023, the largest year in the 2022–2025 window. Revenue then fell 11.6% to KRW 69 billion in 2024 and 6.8% to KRW 64.3 billion in 2025, declining for two straight years.

Operating profit of KRW 1.3 billion in 2022 turned into an operating loss of KRW 7.99 billion in 2023, widened to KRW 9.52 billion in 2024, and narrowed to KRW 6.16 billion in 2025. The operating margin moved from 2.1% in 2022 to -10.2% in 2023, -13.8% in 2024 and -9.6% in 2025.

In 2022, operating profit was KRW 1.3 billion while net income attributable to controlling shareholders was KRW 105.2 billion, so non-operating items played a large role that year.

In 2024, the operating loss widened yet controlling-shareholder net income was KRW 13.1 billion, meaning non-operating results offset the operating shortfall. Net income attributable to controlling shareholders fell 91.1% to KRW 1.17 billion in 2025.

On a quarterly basis, the operating loss was KRW 845 million in the third quarter of 2025 and KRW 2.01 billion in the fourth quarter.

In 2026, revenue was KRW 16.7 billion, KRW 17.1 billion and KRW 19.5 billion in the first through third quarters, and the operating loss was KRW 496 million, KRW 1.56 billion and KRW 662 million.

A half-year report showed the first-half 2026 operating loss down 37.7% from a year earlier, with gross margin improvement and lower financing costs helping the company return to net profit.

Net income attributable to controlling shareholders over the last four quarters totals KRW 7.2 billion, of which KRW 3.41 billion came in the fourth quarter of 2025. Operating cash flow shifted from KRW -4.26 billion in 2024 to KRW 3.88 billion in 2025.

05

Industry analysis

The domestic prescription drug (ETC) market is shaped by hospital prescribing patterns and drug pricing rules, and established products with stable prescribing often support the revenue base. Ilsung IS is a mid-sized pharmaceutical company built around such legacy products.

Unlike large bio-drug makers such as Samsung Biologics or Celltrion, which are growing through biologics production and contract capacity, the company relies more heavily on prescription drug sales and is at an early stage of building contract manufacturing as a new growth axis.

Compared with domestic drugmakers such as Yuhan and Hanmi Pharm, its smaller revenue base means cost structure improvements may show up more visibly in its results.

At the same time, the smaller base also means prescription changes for a single product or raw material cost swings can have a large effect on profit and loss. In its March 2026 plan, the company set raw material cost reduction and in-house production as priorities.

A report on the first half of 2026 described revenue growth alongside a higher gross margin. Industry-wide cycle positioning is difficult to quantify, so the company's product mix and cost improvement trajectory are the main factors shaping its competitive position.

06

Outlook

In its March 2026 corporate value enhancement plan, the company set out revenue growth, improved profit and loss, and a shareholder return policy as its main directions.

On the business side, it set portfolio reshaping focused on profitability, in-house production of key products and raw material cost reduction as priorities. Developing proprietary combination drugs, nurturing new products and expanding contract manufacturing were included as ways to diversify its earnings base.

On capital policy, the board approved the cancellation of 2.66 million common shares on September 30, 2026, and the cancellation was completed on October 13. A move to expand cash dividends is also underway.

Among new businesses, a nursing facility project led by the real estate development unit was reported in August 2024, and senior healthcare, digital therapeutics and asset management are named as expansion areas.

On the pipeline side, one report said the company became the second-largest shareholder in a developer of a therapy for calcific aortic valve disease (CAVD), described as the only such developer worldwide, and that the drug is in global Phase 2b/3a trials.

No confirmed timetable for trial results or commercialization has been disclosed, so it is difficult to include in earnings expectations.

The next checkpoint is the annual revenue mix and operating margin trend in the 2026 annual report, followed by whether revenue growth and narrower operating losses continue in the first-quarter 2027 report.

07

Valuation

PER
19.9×
PBR
0.4×
ROE
1.9%
EPS
₩1,028
BPS
₩53,262
Dividend per share
₩1,200

The price-to-book ratio is below 1x, meaning the stock trades at a discount to net asset value. Total equity of KRW 386.3 billion against total liabilities of KRW 16.7 billion indicates a light debt burden, which supports an asset-based view of financial capacity.

The price-to-earnings ratio, by contrast, is calculated against a small earnings base, so the figure swings widely with the pace of profit recovery. Relative to the Korean pharmaceutical sector average, the dividend yield was well above the industry level in a data set compiled around 2025.

Cancellation of treasury shares reduced the number of common shares outstanding, which changes the basis for per-share comparisons. The cash and equivalents in the 1 trillion-won range also bear on shareholder return capacity.

However, that cash also reflects the cumulative effect of years of operating losses, so it should be read alongside operating cash generation. Valuation will be reassessed against earnings capacity confirmed in the 2026 annual report and the first-quarter 2027 report.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Three Straight Quarters of Revenue Growth

Revenue rose to KRW 16.7 billion, KRW 17.1 billion and KRW 19.5 billion across the first three quarters of 2026, extending a growth run for three straight quarters.

Third-quarter 2026 revenue increased 16.1% from a year earlier, and the operating loss of KRW 662 million was smaller than the KRW 845 million loss in the third quarter of 2025. A half-year report showed the first-half 2026 operating loss down 37.7% from the prior year.

Stronger Shareholder Return Policy

The board resolved on September 30, 2026 to cancel 2.66 million common shares, and the cancellation was completed on October 13. After the cancellation, the number of common shares outstanding fell from 13.3 million to 10.64 million.

Financial Capacity and Cash Flow Turnaround

At the end of 2025, the debt ratio was 4.3%, total liabilities were KRW 16.7 billion and total equity was KRW 386.3 billion. Cash and equivalents in the 100 billion-won range have been cited as a foundation for the earnings recovery. Operating cash flow moved from KRW -4.26 billion in 2024 to KRW 3.88 billion in 2025.

09

Bear factors

Five Consecutive Quarters of Operating Losses

The company posted operating losses for three straight years from 2023 through 2025, with the 2025 operating loss at KRW 6.16 billion. Operating losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. The KRW 2.01 billion operating loss in the fourth quarter of 2025 was the largest among those quarters.

Concentration on a Core Product and Revenue Decline

Results depend heavily on sales of the antibiotic Augmentin. Revenue of KRW 64.3 billion in 2025 was below the KRW 78.1 billion recorded in 2023, and it declined in both 2024 and 2025. On a nine-month basis for 2025, lower tablet and injectable sales drove the overall revenue decline.

Earnings Concentrated in Single Quarters

Over the last four quarters the total is KRW 7.2 billion, and the fourth quarter of 2025 alone accounts for KRW 3.41 billion of it. Net income attributable to controlling shareholders then dropped 86.2% quarter on quarter to KRW 217 million in the second quarter of 2026.

10

Risk factors

Execution Risk in Business Reshaping

The company has set portfolio reshaping, in-house production of key products and raw material cost reduction as priorities. Whether these translate into actual cost gains should be checked through quarterly gross margin and operating loss trends. If execution slips or costs rise first, the narrowing of losses could weaken.

Burden from New Business Investment and M&A

The company is pursuing new businesses in parallel, including senior care, digital therapeutics, asset management and acquisitions of bio start-ups. Broadening the business can raise upfront investment and management costs, which could add to core business losses until profitability is proven. Results from these ventures can be tracked through separate disclosures and quarterly reports.

Balance Between Cash Outflows and Investment Capacity

Treasury share cancellation and a larger dividend increase cash returned to shareholders. Operating cash flow turned positive, but at KRW 3.88 billion in 2025 it is modest relative to large-scale investment. The balance between shareholder returns and new business investment will shape future financial capacity.

11

What to watch next

  1. End of December 2026

    Year-end 2026 closing marks the point at which the product reshaping and in-house production plans will show in the financial statements, to be confirmed in subsequent disclosures.

  2. Late March 2027

    Deadline for the 2026 annual report, which will disclose fourth-quarter and full-year operating loss and margin. Whether the five-quarter run of operating losses is reflected in the annual results is the key point.

  3. March 2027 (annual general meeting period)

    Dividend decisions and shareholder meeting agenda items are finalized. Whether the post-cancellation per-share dividend basis and return size are aligned with earnings recovery is the item to check.

  4. Mid-May 2027

    Filing deadline for the first-quarter 2027 report. Whether three straight quarters of revenue growth, narrowing operating losses and non-operating income changes continue will be checked.

12

Overall view

Ilsung IS's revenue peaked in 2023 and declined through 2025, and it posted operating losses for three straight years starting in 2023. In 2026, revenue rose for three straight quarters and operating losses narrowed.

Shareholder return measures, including the cancellation of 2.66 million treasury shares and an expanded cash dividend, were carried out in the same period. On the financial side, the company has a light debt burden and a large equity base.

Five consecutive quarters of operating losses, concentration on Augmentin and the decline in 2025 net income attributable to controlling shareholders remain weak points. Because the last four quarters of profit are concentrated in a few quarters, quarterly volatility is also high.

The next checkpoint is the annual operating loss and margin in the 2026 annual report, followed by whether revenue growth and narrower losses continue in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. pharmnews.com
  3. comp.wisereport.co.kr
  4. pharmnews.com
  5. hkn24.com
  6. hankyung.com
  7. app.rndcircle.io
  8. medipana.com
  9. m.dailypharm.com
  10. vegannews.co.kr
  11. kr.investing.com
  12. globenewswire.com
  13. vegannews.co.kr
  14. finance.yahoo.com
  15. simplywall.st
  16. judal.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis